CO6741197A2 - Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma - Google Patents

Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma

Info

Publication number
CO6741197A2
CO6741197A2 CO13158425A CO13158425A CO6741197A2 CO 6741197 A2 CO6741197 A2 CO 6741197A2 CO 13158425 A CO13158425 A CO 13158425A CO 13158425 A CO13158425 A CO 13158425A CO 6741197 A2 CO6741197 A2 CO 6741197A2
Authority
CO
Colombia
Prior art keywords
robo1
hepatocarcinoma
treatment
fusion protein
protein
Prior art date
Application number
CO13158425A
Other languages
English (en)
Inventor
Gleizes Frederique Dol
Genevieve Gueguen-Dorbes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45440542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6741197(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR1061163A external-priority patent/FR2969617A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO6741197A2 publication Critical patent/CO6741197A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al uso de una proteína Robo1-Fc para tratar el cáncer, en particular hepatocarcinomas.
CO13158425A 2010-12-23 2013-07-04 Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma CO6741197A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1061163A FR2969617A1 (fr) 2010-12-23 2010-12-23 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs.
EP11306336 2011-10-14

Publications (1)

Publication Number Publication Date
CO6741197A2 true CO6741197A2 (es) 2013-08-30

Family

ID=45440542

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13158425A CO6741197A2 (es) 2010-12-23 2013-07-04 Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma

Country Status (17)

Country Link
US (1) US20130273049A1 (es)
EP (1) EP2655408B1 (es)
JP (1) JP2014507395A (es)
KR (1) KR20130132880A (es)
CN (1) CN103703021A (es)
AR (1) AR084541A1 (es)
AU (1) AU2011347250B2 (es)
CA (1) CA2820781A1 (es)
CL (1) CL2013001861A1 (es)
CO (1) CO6741197A2 (es)
EA (1) EA201390955A1 (es)
MA (1) MA34827B1 (es)
MX (1) MX2013007421A (es)
SG (1) SG191060A1 (es)
UY (1) UY33833A (es)
WO (1) WO2012085178A1 (es)
ZA (1) ZA201305266B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
SG10201605361RA (en) 2012-01-05 2016-08-30 Boston Medical Ct Corp Slit-Robo Signaling for Diagnosis and Treatment of Kidney Disease
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104873986A (zh) * 2015-03-23 2015-09-02 广东药学院 一种治疗肝脏纤维化的siRNA及其应用
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
MX2019014480A (es) * 2017-06-02 2020-01-23 Pfizer Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE69816467T2 (de) * 1997-10-20 2004-04-15 The Regents Of The University Of California, Oakland Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
PT1572169E (pt) 2002-03-08 2013-10-08 Shanghai Inst Biol Sciences Deteção e modulação da angiogénese mediada pela slit e roundabout (robo), e correspondentes utilizações
CN101014860B (zh) * 2004-03-31 2012-01-25 中外制药株式会社 抗-robo1抗体用于制备癌症治疗药物及相关诊断试剂盒
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
CN101821283A (zh) * 2007-09-14 2010-09-01 Scil技术股份有限公司 Slit,nephrin,肝配蛋白或脑信号蛋白用于治疗软骨疾病的用途
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用

Also Published As

Publication number Publication date
EP2655408A1 (en) 2013-10-30
JP2014507395A (ja) 2014-03-27
ZA201305266B (en) 2014-09-25
AU2011347250A1 (en) 2013-05-02
CN103703021A (zh) 2014-04-02
WO2012085178A1 (en) 2012-06-28
CA2820781A1 (en) 2012-06-28
SG191060A1 (en) 2013-07-31
AU2011347250B2 (en) 2015-06-04
MA34827B1 (fr) 2014-01-02
KR20130132880A (ko) 2013-12-05
AR084541A1 (es) 2013-05-22
MX2013007421A (es) 2014-02-03
US20130273049A1 (en) 2013-10-17
EA201390955A1 (ru) 2013-11-29
CL2013001861A1 (es) 2014-04-04
EP2655408B1 (en) 2016-07-06
UY33833A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
CY1120374T1 (el) Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CR20110553A (es) Terapia complementaria contra el cáncer
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
EA201400178A1 (ru) Лечение рака молочной железы
EA201171367A1 (ru) Винилиндазолильные соединения
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
CL2012003385A1 (es) Tratamiento para la incontinencia.
TWD161529S (zh) 治療燈
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
EA201490559A1 (ru) Композиция для лечения свища
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
GB201118656D0 (en) New compounds
EA201270722A1 (ru) Формы рифаксимина и их применение
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
BR112013024211A2 (pt) tratamento de tumores sólidos
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo